The 324 remaining samples tested comprised of 179 (55%) samples reported as positive for either ALK, ROS1, RET fusions and/or MET exon 14 skipping, and 145 (45%) samples reported as negative for these gene alterations by the routine reference method, providing a large sample size to assess both sensitivity and specificity of the IdyllaTM GeneFusion Assay, with different tissues and different fusion compositions, but also offering a unique opportunity to test it against the routine reference methods currently used in routine NSCLC molecular testing. The gene discussed is MET; the disease is non-small cell lung carcinoma.